The COVID-19 pandemic exposed critical vulnerabilities in the global IVD supply chain — from shortages of reagent-grade chemicals and membrane materials to bottlenecks in swab and tube production — that disrupted test availability at precisely the moment demand was highest. The industry has been rebuilding supply chain resilience ever since, but the concentration of raw material manufacturing in China and a small number of specialty chemical suppliers remains a strategic vulnerability. Nitrocellulose membranes for lateral flow tests, monoclonal antibodies, enzymes for molecular assays, and specialty plastics for consumables each have concentrated supply chains that can fail under demand shock. The CHIPS Act parallel in diagnostics — investment in domestic reagent manufacturing capacity — is beginning to emerge as a policy priority in the U.S. and EU.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• IVD Supply Chain Overview — Raw Materials, Components, and Manufacturing Structure
• Nitrocellulose and Membrane Materials — Supply Concentration and Resilience Investment
• Monoclonal Antibodies and Biological Reagents — Manufacturing, Quality, and Supply Strategy
• Enzymes and Molecular Biology Reagents — PCR, NGS, and Isothermal Amplification Supply
• Specialty Plastics and Consumables — Tubes, Swabs, Cards, and Microfluidic Substrates
• Contract Manufacturing — CMO/CDMO Landscape for IVD Reagents and Components
• Post-COVID Lessons — Inventory Strategy, Dual Sourcing, and Emergency Procurement
• Geopolitical Supply Risk — China Dependence, Reshoring, and Near-Shoring Strategies
• Regulatory Requirements — Supply Chain Documentation, IVDR Traceability, and FDA QSR
• Investment and Partnership Opportunities — Supply Chain Technology and Resilience Infrastructure
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most critical supply chain vulnerabilities
- Strategic recommendations
2. IVD Supply Chain Overview
- Supply chain structure — raw materials, components, and finished goods
- Key supply chain vulnerabilities by product category
- Post-COVID supply chain investment and restructuring
3. Raw Material Supply Chain
- Nitrocellulose and membrane materials — supply concentration and resilience
- Monoclonal antibodies and biological reagents — manufacturing and supply strategy
- Enzymes and molecular biology reagents — PCR, NGS, and isothermal amplification supply
- Specialty plastics and consumables — tubes, swabs, and microfluidic substrates
4. Contract Manufacturing
- CMO and CDMO landscape for IVD reagents
- Contract manufacturer capabilities and qualification
- Surge capacity and emergency manufacturing programs
5. Post-COVID Lessons
- Inventory strategy and safety stock policies
- Dual sourcing and supplier diversification
- Emergency procurement frameworks
6. Geopolitical Supply Risk
- China dependence analysis by raw material category
- Reshoring and near-shoring investment programs
- Export controls and tariff exposure management
7. Regulatory Requirements
- IVDR supply chain traceability requirements
- FDA QSR supplier qualification obligations
- Change management for supply chain modifications
8. Digital Supply Chain
- Supply chain visibility platforms
- Demand forecasting and inventory optimization
- Digital twin applications in IVD manufacturing
9. Strategic Recommendations
- Supply chain resilience investment priorities
- Dual sourcing and geographic diversification strategy
- Regulatory compliance and documentation strategy
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. IVD Raw Material Supply Chain — Concentration Risk Assessment by Category
Table 2. Nitrocellulose and Membrane Materials — Supplier Landscape and Risk Assessment
Table 3. Monoclonal Antibodies — Supplier Landscape and Manufacturing Capacity
Table 4. Enzymes and Molecular Biology Reagents — Supplier Landscape and Risk Assessment
Table 5. CMO and CDMO Landscape — IVD Reagent and Component Manufacturing 2025
Table 6. Geopolitical Supply Risk — China Dependence by Raw Material Category
Table 7. Reshoring and Near-Shoring Investment — Leading IVD Supplier Programs 2025
Table 8. IVDR and FDA QSR — Supply Chain Compliance Requirements
Table 9. Digital Supply Chain Platforms — Leading Solutions and Adoption Status
Table 10. Key Risks and Mitigation Strategies
Abbott Diagnostics
Bio-Rad Laboratories
bioMérieux
Danaher (Beckman Coulter, Cepheid, Radiometer)
DiaSorin
Hologic
QuidelOrtho
Roche Diagnostics
Siemens Healthineers
Sysmex
